Investment company Syncona and UCL Business, the technology transfer arm of University College London, have together set up a new player in the CAR-T field, Autolus. Syncona has given the start-up a £30m cash injection to get going.
Autolus's focus will be the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematological and solid tumors. The company...
Welcome to Scrip
Create an account to read this article
Already a subscriber?